Ally Bridge Group’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Ally Bridge Group’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-550,000	Closed	-$2.31M	–	26
2023 Q1	$2.31M	Buy	+550,000	New	+$2.85M	3.03%	11

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Ally Bridge Group's CTIC Position: Q2 2023 in Review

Ally Bridge Group sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 550,000 shares — an estimated $2.31M sold.

Ally Bridge Group first reported a position in CTIC in Q1 2023 and held it in 1 quarter. The position peaked at $2.31M in Q1 2023. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Ally Bridge Group reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Ally Bridge Group sold 550,000 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $2.31M.
Ally Bridge Group first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2023 and held it in 1 quarter.
Ally Bridge Group's CTI BioPharma Corp. (DE) Common Stock position peaked at $2.31M in Q1 2023.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Ally Bridge Group's 13F filing for Q2 2023, filed 14 Aug 2023.